Loss of TNFAIP3 enhances MYD88(L265P)-driven signaling in non-Hodgkin lymphoma

MYD88 mutations are one of the most recurrent mutations in hematologic malignancies. However, recent mouse models suggest that MYD88(L265P) alone may not be sufficient to induce tumor formation. Interplay between MYD88(L265P) and other genetic events is further supported by the fact that TNFAIP3 (A2...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood Cancer J
Prif Awduron: Wenzl, Kerstin, Manske, Michelle K., Sarangi, Vivekananda, Asmann, Yan W., Greipp, Patricia T., Schoon, Hanna R., Braggio, Esteban, Maurer, Matthew J., Feldman, Andrew L., Witzig, Thomas E., Slager, Susan L., Ansell, Stephen M., Cerhan, James R., Novak, Anne J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group UK 2018
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6177394/
https://ncbi.nlm.nih.gov/pubmed/30301877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-018-0130-3
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg